Immunovant (IMVT) News and press releases

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023

31 Mar 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Piper Sandler Initiates Coverage On Immunovant with Overweight Rating, Announces Price Target of $28

31 Mar 23

News, Price Target, Initiation, Analyst Ratings

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Immunovant (NASDAQ:IMVT) with a Overweight rating and announces Price Target of $28.

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023

30 Mar 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

7 Analysts Have This to Say About Immunovant

30 Mar 23

Analyst Ratings

Stifel Initiates Coverage On Immunovant with Buy Rating, Announces Price Target of $28

30 Mar 23

News, Price Target, Initiation, Analyst Ratings

Stifel analyst Alex Thompson initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price Target of $28.

Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment

20 Mar 23

Analyst Color, Health Care, Price Target, Reiteration, Analyst Ratings, Movers, Trading Ideas, General

HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $26

20 Mar 23

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $21 to $26.

Immunovant Could Potentially Be An M&A Target, Writes Analyst

15 Feb 23

Analyst Color, Biotech, News, Health Care, Price Target, Initiation, Analyst Ratings, Movers, Trading Ideas, General

Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023

15 Feb 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Cantor Fitzgerald Initiates Coverage On Immunovant with Overweight Rating, Announces Price Target of $30

15 Feb 23

News, Price Target, Initiation, Analyst Ratings

Cantor Fitzgerald analyst Louise Chen initiates coverage on Immunovant (NASDAQ:IMVT) with a Overweight rating and announces Price Target of $30.

Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023

13 Feb 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Guggenheim Upgrades Immunovant to Buy

13 Feb 23

News, Upgrades, Analyst Ratings

Guggenheim analyst Yatin Suneja upgrades Immunovant (NASDAQ:IMVT) from Neutral to Buy.

Analyst Expectations for Immunovant's Future

7 Feb 23

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $21

7 Feb 23

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $17 to $21.

SVB Leerink Maintains Outperform on Immunovant, Raises Price Target to $21

6 Feb 23

News, Price Target, Analyst Ratings

SVB Leerink analyst Thomas Smith maintains Immunovant (NASDAQ:IMVT) with a Outperform and raises the price target from $14 to $21.

Chardan Capital Maintains Buy on Immunovant, Raises Price Target to $21

6 Feb 23

News, Price Target, Analyst Ratings

Chardan Capital analyst Matthew Barcus maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $19 to $21.

Wells Fargo Upgrades Immunovant to Overweight, Raises Price Target to $27

3 Jan 23

News, Upgrades, Price Target, Analyst Ratings

Wells Fargo analyst Derek Archila upgrades Immunovant (NASDAQ:IMVT) from Equal-Weight to Overweight and raises the price target from $10 to $27.

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

3 Feb 23

Earnings, Press Releases

A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in chronic inflammatory